# Biotech
Latest news and articles about Biotech
Total: 5 articles found
The Price of Ambiguity: Why China’s Cardiovascular Giant Salubris is Crashing
Shenzhen Salubris Pharmaceuticals shares hit consecutive limit-down floors after its flagship heart failure drug failed to show statistically significant results in Phase II trials. The sell-off reflects growing investor impatience with China's biotech sector as companies struggle to transition from generics to true innovation.
Semiconductor Surge Buffers Hong Kong Markets as Biotech Falters Amid Regulatory Headwinds
Hong Kong's Hang Seng Index remained flat as a 6% rally in semiconductor giants SMIC and Hua Hong was offset by a sharp decline in the biotech sector. Positive industrial profit data from the mainland provided a floor for the market amidst ongoing regulatory shifts in the healthcare industry.
China’s Pharma Roadmap: Beijing Unveils Strategic Pivot to High-Value Innovation and AI Integration
China's MIIT has announced the framework for the 15th Five-Year Plan for the pharmaceutical industry, focusing on accelerating drug innovation, lowering prices through AI integration, and addressing the needs of elderly and rare-disease patients. The policy aims to balance industrial growth with public affordability while positioning Chinese biotech as a competitive global force.
AbbVie Taps Chinese Innovation in $745 Million Bet on Next-Generation Pain Relief
Haisco Pharmaceutical has signed a global licensing deal with AbbVie for its Nav1.8 pain inhibitor, worth up to $745 million. The agreement grants AbbVie exclusive rights outside of Greater China and highlights the shift toward Chinese-developed innovative therapies in the global market.
NVIDIA’s Strategic Gambit and Biotech M&A Surge Fuel Wall Street Rally
US markets opened strongly on March 31, 2026, driven by NVIDIA’s $2 billion investment in Marvell and a massive wave of biotech acquisitions by Biogen and Eli Lilly. This tech and healthcare-led rally stands in stark contrast to European markets, which faced a double-digit decline over the course of the month.